Clinical trials: Neurocognitive Disorder
Mild Cognitive Impairment, Alzheimer Disease
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
This is a proof of concept observational study is to determine if there is correlation between Aβ plaques and vascular findings in the Retina versus brain ARIA.
- Trial name
- NCT06400368
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- NeuroVision Imaging
Sleep Initiation and Maintenance Disorders, Alzheimer Disease
Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)
This study aims to examine the safety and efficacy of suvorexant (MK-4305) to improve sleep in individuals with Alzheimer's disease (AD).
- Trial name
- NCT02750306
- Testing
- Suvorexant
- Volunteers
- 285 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease
Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease
The purpose of this study is to determine if multiple immunizations with Lu AF20513 is tolerable and safe in patients with mild Alzheimer's disease.
- Trial name
- NCT02388152
- Testing
- Lu AF20513, low dose, Lu AF20513, medium dose, Lu AF20513, high dose
- Where
- 5 sites in Austria, Finland and 1 more
- Volunteers
- 50 people
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease
Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)
Re-read of brain amyloid scans acquired in previous AV-45 clinical studies by readers trained using updated reading methodology.
- Trial name
- NCT01565382
- Testing
- florbetapir F 18
- Volunteers
- 40 people
- Sponsor
- Avid Radiopharmaceuticals
Moderate Alzheimer's Disease
GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)
The current study is being conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered subcutaneously as a treatment for moderate Alzheimer's disease (AD).
- Trial name
- NCT03959553
- Testing
- GV1001, Normal saline
- Sponsor
- GemVax & Kael
Alzheimer Disease
[18F]PI-2620 Phase 3 Histopathological Study
This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and…
- Trial name
- NCT05641688
- Testing
- [18F]PI-2620
- Where
- 25 sites in United States
- Volunteers
- 200 people
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer's Disease, Dementia
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease
The purpose of this study is to assess the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo for the treatment of patients with hallucinations and delusions associated with Alzheimer's disease.
- Trial name
- NCT00287742
- Testing
- risperidone
- Volunteers
- 33 people
- Sponsor
- Janssen Pharmaceutical K.K.
Alzheimer Disease
A Single Dose Escalation Study of HHT201 in Healthy Subjects
The objective of this study is to evaluate the safety and pharmacokinetic profiles of HHT201 in healthy subjects.
- Trial name
- NCT06373094
- Testing
- Donepezil Dihydroxynaphthalate for Injection
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Shanghai Synergy Pharmaceutical Sciences Co., Ltd.
Alzheimer's Disease
A Safety Study of LY2886721 Multiple Doses in Healthy Subjects
This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2886721 multiple doses, how the body handles the drug, and the drug's effect on the body.
- Trial name
- NCT01227252
- Testing
- LY2886721
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Huntington Disease
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington's Disease (HD).
- Trial name
- NCT05686551
- Testing
- Tominersen
- Where
- 70 sites in United States, Argentina and 13 more
- Volunteers
- 301 people
- Sponsor
- Hoffmann-La Roche
Huntington Disease
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies
This study will evaluate the long-term safety and tolerability of RO7234292 (RG6042) in participants who have completed other F.
- Trial name
- NCT03842969
- Testing
- RO7234292 (RG6042)
- Where
- 38 sites in United States, Austria and 6 more
- Volunteers
- 236 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease
A Study of SHR-1707 With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
This study aims to evaluate the safety, tolerability and pharmacodynamics of intravenous administration of SHR-1707 In patients with mild cognitive impairment due to Alzheimer's Disease or mild Alzheimer's Disease.
- Trial name
- NCT05681819
- Testing
- SHR-1707
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Alzheimer Disease
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 weeks.
- Trial name
- REFOCUS-ALZ (NCT05026177)
- Testing
- Simufilam
- Where
- 89 sites in United States, Canada and 2 more
- Volunteers
- 1,125 people
- Sponsor
- Cassava Sciences, Inc.
Agitation, Dementia
An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia
A randomized, double-blind, placebo-controlled parallel group 3-arm study assessing efficacy, safety, and tolerability of two doses BXCL501 in male and female geriatric residents (65 years and older) with acute agitation…
- Trial name
- NCT05276830
- Testing
- BXCL501
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- BioXcel Therapeutics Inc
Alzheimer's Disease
A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
The purpose of this study is to examine the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single dose of PF-04360365 in Japanese subjects with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00607308
- Testing
- PF-04360365
- Where
- 9 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Pfizer
Alzheimer's Disease
Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia
This study will evaluate the performance of Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) in patients with Alzheimer's disease (AD).
- Trial name
- ALFO-AD (NCT03441516)
- Testing
- Alfoatirin® Tab. + Aripezil® Tab., Aripezil® Tab.
- Where
- 6 sites in South Korea
- Volunteers
- 79 people
- Sponsor
- Yuhan Corporation
Alzheimer's Disease
PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy Volunteers
The present pharmacokinetic study is designed to further characterise the pharmacokinetics of the RSG XR formulation and aims to assess dose proportionality, strength equivalence, the food effect and the pharmacokinetics after…
- Trial name
- Rosi XR (NCT00733785)
- Testing
- Rosiglitazone XR
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects
A Randomized, Double-blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients with Early Alzheimer's Disease
- Trial name
- NCT03817684
- Testing
- BPN14770
- Where
- 41 sites in United States
- Volunteers
- 255 people
- Sponsor
- Tetra Discovery Partners
Alzheimer's Disease
A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED)
This study will evaluate the performance of the CogState computerized neuropsychological battery, Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) and Alzheimer's Disease Cooperative Study - Activities of Daily…
- Trial name
- NCT00777608
- Testing
- Donepezil 5 - 10 mg, Donepezil 10 mg
- Volunteers
- 106 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease
The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease
This is a 15-month study with two phases. During the first 12-month phase of this study, patients will be randomly assigned to receive either active study drug or placebo (approximately half of all patients will be on active…
- Trial name
- NCT00006187
- Testing
- Investigational drug
- Where
- 34 sites in United States
- Sponsor
- Merck Sharp & Dohme LLC